{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:50:33Z","timestamp":1792619433892,"version":"4.5.0"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>\n                      Here we review recent literature on the emerging role of nicotinamide adenine dinucleotide (NAD\n                      <jats:sup>+<\/jats:sup>\n                      ) metabolism and its dysfunction via the enzyme CD38 in the pathogenesis of rheumatologic diseases. We evaluate the potential of targeting CD38 to ameliorate NAD\n                      <jats:sup>+<\/jats:sup>\n                      -related metabolic imbalance and tissue dysfunction in the treatment of systemic sclerosis (SSc), systemic lupus erythematous (SLE), and rheumatoid arthritis (RA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      In this review, we will discuss emerging basic, preclinical, and human data that point to the novel role of CD38 in dysregulated NAD\n                      <jats:sup>+<\/jats:sup>\n                      -homeostasis in SSc, SLE, and RA. In particular, recent studies implicate increased activity of CD38, one of the main enzymes in NAD\n                      <jats:sup>+<\/jats:sup>\n                      catabolism, in the pathogenesis of persistent systemic fibrosis in SSc, and increased susceptibility of SLE patients to infections. We will also discuss recent studies that demonstrate that a cytotoxic CD38 antibody can promote clearance of plasma cells involved in the generation of RA antibodies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>\n                      Recent studies identify potential therapeutic approaches for boosting NAD\n                      <jats:sup>+<\/jats:sup>\n                      to treat rheumatologic diseases including SSc, RA, and SLE, with particular attention to inhibition of CD38 enzymatic activity as a target. Key future directions in the field include the determination of the cell-type specificity and role of CD38 enzymatic activity versus CD38 structural roles in human diseases, as well as the indicators and potential side effects of CD38-targeted treatments.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000737","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T14:23:25Z","timestamp":1600266205000},"page":"488-496","source":"Crossref","is-referenced-by-count":35,"title":["The NADase enzyme CD38: an emerging pharmacological target for systemic sclerosis, systemic lupus erythematosus and rheumatoid arthritis"],"prefix":"10.1097","volume":"32","author":[{"given":"Thais Ribeiro","family":"Peclat","sequence":"first","affiliation":[{"name":"Signal Transduction and Molecular Nutrition Laboratory, Kogod Aging Center, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shi","sequence":"additional","affiliation":[{"name":"Northwestern Scleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[{"name":"Northwestern Scleroderma Program, Feinberg School of Medicine, Northwestern University, Chicago, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Nunes","family":"Chini","sequence":"additional","affiliation":[{"name":"Signal Transduction and Molecular Nutrition Laboratory, Kogod Aging Center, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,15]]},"reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcdb.2019.12.007","article-title":"Rationally-based therapeutic disease modification in systemic sclerosis: novel strategies","volume":"101","author":"Asano","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/BOR.0000000000000594","article-title":"Pathogenesis and treatment of autoimmune rheumatic diseases","volume":"31","author":"Liu","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molmed.2011.10.005","article-title":"Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus","volume":"18","author":"Grammatikos","year":"2012","journal-title":"Trends Mol Med"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mce.2016.11.003","article-title":"NAD and the aging process: role in life, death and everything in between","volume":"455","author":"Chini","year":"2017","journal-title":"Mol Cell Endocrinol"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aac4854","article-title":"NAD+ in aging, metabolism, and neurodegeneration","volume":"350","author":"Verdin","year":"2015","journal-title":"Science"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.cell.2013.11.037","article-title":"Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging","volume":"155","author":"Gomes","year":"2013","journal-title":"Cell"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cmet.2016.05.006","article-title":"CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism","volume":"23","author":"Camacho-Pereira","year":"2016","journal-title":"Cell Metab"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"R10-20230829","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1056\/NEJMoa1616361","article-title":"NAD deficiency, congenital malformations, and niacin supplementation","volume":"377","author":"Shi","year":"2017","journal-title":"N Engl J Med"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"1081.e10","DOI":"10.1016\/j.cmet.2018.03.016","article-title":"A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD","volume":"27","author":"Tarrag\u00f3","year":"2018","journal-title":"Cell Metab"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"112.e4","DOI":"10.1016\/j.celrep.2019.12.014","article-title":"The CD38\/NAD\/SIRTUIN1\/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections","volume":"30","author":"Katsuyama","year":"2020","journal-title":"Cell Rep"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s42255-019-0161-5","article-title":"NAD+ homeostasis in health and disease","volume":"2","author":"Katsyuba","year":"2020","journal-title":"Nat Metab"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"100022","DOI":"10.1016\/j.jtauto.2019.100022","article-title":"CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients","volume":"2","author":"Frerichs","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-018-1578-z","article-title":"Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich predisease and established rheumatoid arthritis and systemic lupus erythematosus","volume":"20","author":"Cole","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cmet.2014.11.003","article-title":"Activation of SIRT3 by the NAD+ precursor nicotinamide riboside protects from noise-induced hearing loss","volume":"20","author":"Brown","year":"2014","journal-title":"Cell Metab"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.cell.2010.10.002","article-title":"Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction","volume":"143","author":"Someya","year":"2010","journal-title":"Cell"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1096\/fj.07-8290com","article-title":"The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity","volume":"21","author":"Barbosa","year":"2007","journal-title":"FASEB J"},{"key":"R20-20230829","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cmet.2012.04.022","article-title":"The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity","volume":"15","author":"Cant\u00f3","year":"2012","journal-title":"Cell Metab"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmet.2011.08.014","article-title":"Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice","volume":"14","author":"Yoshino","year":"2011","journal-title":"Cell Metab"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"26933","DOI":"10.1038\/srep26933","article-title":"Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice","volume":"6","author":"Trammell","year":"2016","journal-title":"Sci Rep"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1681\/ASN.2016040385","article-title":"Nicotinamide mononucleotide, an NAD(+) precursor","volume":"28","author":"Guan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R24-20230829","first-page":"3342","article-title":"Exogenous NAD(+) administration significantly protects against myocardial ischemia\/reperfusion injury in rat model","volume":"8","author":"Zhang","year":"2016","journal-title":"Am J Transl Res"},{"key":"R25-20230829","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/jcmm.13076","article-title":"CD38 promotes angiotensin II-induced cardiac hypertrophy","volume":"21","author":"Guan","year":"2017","journal-title":"J Cell Mol Med"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yjmcc.2018.02.015","article-title":"Genetic deletion of CD38 confers postischemic myocardial protection through preserved pyridine nucleotides","volume":"118","author":"Boslett","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"R27-20230829","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1161\/CIRCULATIONAHA.116.022495","article-title":"Normalization of NAD+ redox balance as a therapy for heart failure","volume":"134","author":"Lee","year":"2016","journal-title":"Circulation"},{"key":"R28-20230829","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/hep.28245","article-title":"Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice","volume":"63","author":"Gariani","year":"2016","journal-title":"Hepatology"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.yexmp.2016.02.004","article-title":"Chronic alcohol binging injures the liver and other organs by reducing NAD+ levels required for sirtuin's deacetylase activity","volume":"100","author":"French","year":"2016","journal-title":"Exp Mol Pathol"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"361ra139","DOI":"10.1126\/scitranslmed.aaf5504","article-title":"NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation","volume":"8","author":"Ryu","year":"2016","journal-title":"Sci Transl Med"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cmet.2014.04.001","article-title":"NAD(+)-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease","volume":"19","author":"Cerutti","year":"2014","journal-title":"Cell Metab"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1178646918776658","DOI":"10.1177\/1178646918776658","article-title":"The influence of nicotinamide on health and disease in the central nervous system","volume":"11","author":"Fricker","year":"2018","journal-title":"Int J Tryptophan Res"},{"key":"R33-20230829","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1126\/science.1258366","article-title":"SARM1 activation triggers axon degeneration locally via NAD+ destruction","volume":"348","author":"Gerdts","year":"2015","journal-title":"Science"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nbd.2016.07.018","article-title":"Nicotinamide mononucleotide inhibits postischemic NAD(+) degradation and dramatically ameliorates brain damage following global cerebral ischemia","volume":"95","author":"Park","year":"2016","journal-title":"Neurobiol Dis"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jneuroim.2018.05.002","article-title":"Niacin modulates macrophage polarization in Parkinson's disease","volume":"320","author":"Wakade","year":"2018","journal-title":"J Neuroimmunol"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/acel.12461","article-title":"Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice","volume":"15","author":"de Picciotto","year":"2016","journal-title":"Aging Cell"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.aaf2693","article-title":"NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice","volume":"352","author":"Zhang","year":"2016","journal-title":"Science"},{"key":"R38-20230829","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.cmet.2014.10.005","article-title":"A high-fat diet and NAD+ activate Sirt1 to rescue premature aging in Cockayne syndrome","volume":"20","author":"Scheibye-Knudsen","year":"2014","journal-title":"Cell Metab"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1126\/science.aal0092","article-title":"Vitamin B(3) modulates mitochondrial vulnerability and prevents glaucoma in aged mice","volume":"355","author":"Williams","year":"2017","journal-title":"Science"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/ng.2356","article-title":"Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration","volume":"44","author":"Koenekoop","year":"2012","journal-title":"Nat Genet"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41591-018-0138-z","article-title":"De novo NAD+ biosynthetic impairment in acute kidney injury in humans","volume":"24","author":"Poyan Mehr","year":"2018","journal-title":"Nat Med"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/s41591-018-0181-9","article-title":"Modulating NAD+ metabolism to prevent acute kidney injury","volume":"24","author":"Bulluck","year":"2018","journal-title":"Nat Med"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1042\/bj0960837","article-title":"Nicotinamide nucleotides in the erythrocytes of patients suffering from pellagra","volume":"96","author":"Raghuramulu","year":"1965","journal-title":"Biochem J"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"302875","DOI":"10.1155\/2012\/302875","article-title":"Nicotinamide, NAD(P)(H), and methyl-group homeostasis evolved and became a determinant of ageing diseases: hypotheses and lessons from pellagra","volume":"2012","author":"Williams","year":"2012","journal-title":"Curr Gerontol Geriatr Res"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"1078.e5","DOI":"10.1016\/j.cmet.2020.04.008","article-title":"Niacin cures systemic NAD + deficiency and improves muscle performance in adult-onset mitochondrial myopathy","volume":"31","author":"Pirinen","year":"2020","journal-title":"Cell Metab"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-018-0724-6","article-title":"Sirtuins and accelerated aging in scleroderma","volume":"20","author":"Wyman","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cmet.2018.02.011","article-title":"Therapeutic potential of NAD-boosting molecules: the in vivo evidence","volume":"27","author":"Rajman","year":"2018","journal-title":"Cell Metab"},{"key":"R48-20230829","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.cmet.2020.05.013","article-title":"Of mice and men: NAD+ boosting with niacin provides hope for mitochondrial myopathy Patients","volume":"31","author":"Chini","year":"2020","journal-title":"Cell Metab"},{"key":"R49-20230829","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1021\/bi201509f","article-title":"Catalysis-based inhibitors of the calcium signaling function of CD38","volume":"51","author":"Kwong","year":"2012","journal-title":"Biochemistry"},{"key":"R50-20230829","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1016\/j.bmcl.2011.05.022","article-title":"Flavonoids as inhibitors of human CD38","volume":"21","author":"Kellenberger","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"R51-20230829","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/ijc.29095","article-title":"Inhibition of glioma progression by a newly discovered CD38 inhibitor","volume":"136","author":"Blacher","year":"2015","journal-title":"Int J Cancer"},{"key":"R52-20230829","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1021\/acs.jmedchem.5b00992","article-title":"Discovery of 4-amino-8-quinoline carboxamides as novel, submicromolar inhibitors of NAD-hydrolyzing enzyme CD38","volume":"58","author":"Becherer","year":"2015","journal-title":"J Med Chem"},{"key":"R53-20230829","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"R54-20230829","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"issue":"(1 Suppl)","key":"R55-20230829","doi-asserted-by":"crossref","first-page":"127.17","DOI":"10.4049\/jimmunol.198.Supp.127.17","article-title":"CD38+ cell depletion with TAK-079 reduces arthritis in a cynomolgus collagen-induced arthritis (CIA) model","volume":"198","author":"Smithson","year":"2017","journal-title":"J Immunol"},{"key":"R56-20230829","doi-asserted-by":"crossref","first-page":"637","DOI":"10.4081\/cp.2014.637","article-title":"Pellagra: a noneradicated old disease","volume":"4","author":"Savvidou","year":"2014","journal-title":"Clin Pract"},{"key":"R57-20230829","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R58-20230829","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/030006057700500401","article-title":"Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena","volume":"5","author":"Ring","year":"1977","journal-title":"J Int Med Res"},{"key":"R59-20230829","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.3390\/ijms20235946","article-title":"Role of nicotinamide in genomic stability and skin cancer chemoprevention","volume":"20","author":"Fania","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R60-20230829","doi-asserted-by":"crossref","first-page":"1334.e5","DOI":"10.1016\/j.neuron.2017.02.022","article-title":"The SARM1\u200atoll\/interleukin-1 receptor domain possesses intrinsic NAD","volume":"93","author":"Essuman","year":"2017","journal-title":"Neuron"},{"key":"R61-20230829","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/bies.1074","article-title":"A cellular survival switch: poly(ADP-ribosyl)ation stimulates DNA repair and silences transcription","volume":"23","author":"Ziegler","year":"2001","journal-title":"Bioessays"},{"key":"R62-20230829","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1089\/gtmb.2016.0007","article-title":"Genetic association of PARP15 polymorphisms with clinical outcome of acute myeloid leukemia in a Korean population","volume":"20","author":"Lee","year":"2016","journal-title":"Genet Test Mol Biomarkers"},{"key":"R63-20230829","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The multifaceted ecto-enzyme CD38: roles in immunomodulation, cancer, aging, and metabolic diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Front Immunol"},{"key":"R64-20230829","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-019-0184-z","article-title":"Emerging targets of disease-modifying therapy for systemic sclerosis","volume":"15","author":"Volkmann","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R65-20230829","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","article-title":"Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities","volume":"8","author":"Bhattacharyya","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"R66-20230829","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"R67-20230829","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","article-title":"Recent developments in myofibroblast biology: paradigms for connective tissue remodeling","volume":"180","author":"Hinz","year":"2012","journal-title":"Am J Pathol"},{"key":"R68-20230829","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41584-019-0322-7","article-title":"Shared and distinct mechanisms of fibrosis","volume":"15","author":"Distler","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R69-20230829","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","article-title":"The histone deacetylase sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor \u03b2 signaling","volume":"67","author":"Wei","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R70-20230829","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41586-019-1173-8","article-title":"Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts","volume":"569","author":"Eckert","year":"2019","journal-title":"Nature"},{"key":"R71-20230829","doi-asserted-by":"crossref","first-page":"i55","DOI":"10.1093\/rheumatology\/kew427","article-title":"Pathways leading to an immunological disease: systemic lupus erythematosus","volume":"56","author":"Zharkova","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R72-20230829","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbrc.2006.08.066","article-title":"Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38","volume":"349","author":"Aksoy","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"R73-20230829","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-018-0122-2","article-title":"Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential","volume":"6","author":"Gan","year":"2018","journal-title":"Biomark Res"},{"key":"R74-20230829","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/cells9010228","article-title":"Roles of CD38 in the immune response to infection","volume":"9","author":"Glar\u00eda","year":"2020","journal-title":"Cells"},{"key":"R75-20230829","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11926-014-0419-6","article-title":"Preclinical rheumatoid arthritis (autoantibodies): an updated review","volume":"16","author":"Deane","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"R76-20230829","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.immunol.24.021605.090517","article-title":"B cell immunobiology in disease: evolving concepts from the clinic","volume":"24","author":"Martin","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"R77-20230829","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrrheum.2016.158","article-title":"Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE","volume":"12","author":"D\u00f6rner","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"R78-20230829","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nrneph.2016.20","article-title":"Plasma cells as an innovative target in autoimmune disease with renal manifestations","volume":"12","author":"Hiepe","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"R79-20230829","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fmed.2018.00339","article-title":"The clinical value of autoantibodies in rheumatoid arthritis","volume":"5","author":"Bugatti","year":"2018","journal-title":"Front Med (Lausanne)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000737","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T03:14:47Z","timestamp":1693278887000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000737","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}